9.91
3.34%
+0.32
After Hours:
9.91
Arcutis Biotherapeutics Inc stock is currently priced at $9.91, with a 24-hour trading volume of 3.72M.
It has seen a +3.34% increased in the last 24 hours and a -4.80% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $9.54 pivot point. If it approaches the $10.12 resistance level, significant changes may occur.
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Arcutis Biotherapeutics Inc (ARQT) Revenue 2023
ARQT reported a revenue (TTM) of $59.61 million for the quarter ending December 31, 2023.
Arcutis Biotherapeutics Inc (ARQT) Net Income 2023
ARQT net income (TTM) was -$262.14 million for the quarter ending December 31, 2023, a +15.83% increase year-over-year.
Arcutis Biotherapeutics Inc (ARQT) Cash Flow 2023
ARQT recorded a free cash flow (TTM) of -$247.49 million for the quarter ending December 31, 2023, a +11.93% increase year-over-year.
Arcutis Biotherapeutics Inc (ARQT) Earnings per Share 2023
ARQT earnings per share (TTM) was -$3.92 for the quarter ending December 31, 2023, a +30.62% growth year-over-year.
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks Investment Research
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
Zacks Investment Research
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Benzinga
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
GlobeNewswire Inc.
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
GlobeNewswire Inc.
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.
Cap:
|
Volume (24h):